

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山医药集团股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## **ELECTION OF THE SUPERVISOR REPRESENTING THE EMPLOYEES OF THE 8TH SESSION OF THE SUPERVISORY COMMITTEE**

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) announces that at the enlarge meeting of the second session of the Labour Union Committee of the Company held on 17 June 2020, Mr. Cai Ruiyu (“**Mr. Cai**”), the exiting supervisor representing the employees, was elected as the supervisor representing the employees of the eighth session of the supervisory committee of the Company. Set out below is the information on Mr. Cai.

### **PERSONAL PARTICULARS**

Mr. Cai Ruiyu, aged 53, holds a master degree in business administration. He is an accountant and financial economist. Mr. Cai started his career in July 1988 and served as the financial controller of Guangzhou Baiyunshan Chinese Medicine Factory (廣州白雲山中藥廠), the chief financial officer of Bozhou Branch, the manager of production scheduling office, and the deputy manager of production technology department, the assistant to the general manager, member of the party committee and deputy general manager of Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (廣州白雲山和記黃埔中藥有限公司), and deputy director of the organization department, human resources department, united front work department and etc. of the Company. Mr. Cai is now serving as the director of the organization department, human resources department, united front work department and etc. of the Company. Mr. Cai has more than 30 years of work experience in financial management, production operation management, human resources and administrative management, and party political work and management, and has extensive experience in party building innovation, administrative management, operation management, and cadre and talent management.

### **TERMS OF OFFICE**

The term of office of Mr. Cai as a member of the 8th session of the supervisory committee shall be the same with those members of the 8th session of the supervisory committee to be elected at the 2019 annual general meeting (“**AGM**”) of the Company. On this basis, it is expected that the term of office of Mr. Cai as a member of the 8th session of the supervisory committee of the Company will be approximately three years. The Company will enter into a service agreement with Mr. Cai.

## **REMUNERATION**

Because Mr. Cai is serving as the director of the organization department, human resources department, united front work department and etc. of the Company at the same time, the emoluments payable to him for year 2020 are estimated to be not exceeding RMB1,200,000, including but not limited to the basic salary, welfare benefits as well as settlement of annual salary for the previous year, etc. The actual emoluments should also be assessed and adjusted according to the Administrative Measures for Emoluments and Performance Appraisal of Senior Management of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited. The said emoluments are emoluments before tax and the individual income tax payable shall be withheld and paid by the Company. The term of office of Mr. Cai as a member of the 8th session of the supervisory committee is expected to be the same with those members of the 8th session of the supervisory committee to be elected at the AGM of the Company, and the emoluments payable to Mr. Cai for year 2020 shall be determined with reference to his actual term of office and employment status.

## **INTERESTS IN THE SHARES OF THE COMPANY WITHIN THE MEANING OF PART XV OF THE SFO**

None of Mr. Cai and his associates have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (“SFO”).

## **NO OTHER INFORMATION REQUIRED TO BE DISCLOSED**

Save as disclosed in the preceding sections of this announcement, as at the date of this announcement, Mr. Cai:

- (a) does not have any relationship with any directors of the Company, other supervisors of the Company, senior management or substantial or controlling shareholders of the Company;
- (b) does not have, and is not deemed to have, any interests in the shares of the Company within the meaning of Part XV of the SFO;
- (c) does not have any directorships held in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas;
- (d) does not hold any position in the Company or the subsidiaries of the Company; and
- (e) does not have other matters that need to be brought to the attention of the shareholders of the Company and there is no information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The other two supervisors representing the shareholders of the supervisory committee of the Company will be elected at the AGM of the Company to be held on 29 June 2020.

The Board of  
**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 18 June 2020

*As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Ms. Cheng Ning, Mr. Yang Jun, Ms. Liu Juyan, Mr. Li Hong, Mr. Wu Changhai and Mr. Zhang Chunbo as executive directors, and Mr. Chu Xiaoping, Mr. Jiang Wenqi, Mr. Wong Hin Wing and Ms. Wang Weihong as independent non-executive directors.*